Status:
COMPLETED
Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea
Lead Sponsor:
University of Cape Town
Collaborating Sponsors:
Natal Bioproducts Institute
Conditions:
Sydenham Chorea
Post Streptococcal Movement Disorder
Eligibility:
All Genders
4-16 years
Phase:
NA
Brief Summary
Children are at risk of developing an involuntary movement disorder after streptococcal throat infections. Not all children are affected and the severity is individually variable. Affected children ha...
Detailed Description
INTRODUCTION Acute Rheumatic Fever (ARF), chronic rheumatic heart disease (RHD) and neuropsychiatric/ movement disorders related to group A beta haemolytic streptococcal infections (GABAS) remain majo...
Eligibility Criteria
Inclusion
- Sydenham chorea moderate to severe (affecting activities of daily living) Raised ASOT titre
Exclusion
- Mild Sydenham chorea (not affecting activities of daily living)
- Exclusion of systemic lupus erythematosus
- Exclusion of Wilson's disease
- Exclusion of toxin ingestion
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00615797
Start Date
May 1 2002
End Date
December 1 2009
Last Update
December 4 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Red Cross Children's Hospital
Cape Town, Western Cape, South Africa, 7700